Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Return on Equity (2017 - 2025)

Anaptysbio filings provide 9 years of Return on Equity readings, the most recent being 0.04% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 183.0% year-over-year to 0.04%, compared with a TTM value of 0.04% through Dec 2025, up 183.0%, and an annual FY2025 reading of 0.0%, up 183.0% over the prior year.
  • Return on Equity hit 0.04% in Q4 2025 for Anaptysbio, down from 2.29% in the prior quarter.
  • The five-year high for Return on Equity was 24.78% in Q2 2025, with the low at 2.68% in Q1 2025.
  • Median Return on Equity over the past 5 years was 0.18% (2022), compared with a mean of 0.92%.
  • The largest YoY upside for Return on Equity was 2501bps in 2025 against a maximum downside of -269bps in 2025.
  • Year by year, Return on Equity stood at 0.15% in 2021, then tumbled by -162bps to 0.4% in 2022, then skyrocketed by 110bps to 0.04% in 2023, then crashed by -4639bps to 1.87% in 2024, then surged by 98bps to 0.04% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.04%, 2.29%, and 24.78% for Q4 2025, Q3 2025, and Q2 2025 respectively.